Resource Overview:
Discover the cutting-edge capabilities of biolayer interferometry (BLI) assays with the Octet® R8e, ideal for scientists focusing on small-molecule interactions. This document initially explores the sensitivity improvements that empower BLI assays to precisely measure kinetic interactions and affinity values of sulfonamide-based inhibitors targeting carbonic anhydrase II (CAII). Traditionally constrained by sensitivity limitations, BLI technology now showcases significant advancements, enabling precise detection of even subtle binding interactions.
The document then features a comparative analysis using sulfonamide compounds such as acetazolamide and furosemide, demonstrating how BLI assays with the Octet® R8e align closely with established SPR data. This validation emphasizes BLI's capability to deliver reliable kinetic and affinity results, essential for understanding structure-activity relationships in drug discovery.
Key Takeaways:
- Enhanced Sensitivity: The Octet® R8e offers precise measurement of small-molecule interactions, overcoming traditional limitations.
- SPR Validation: BLI assays with the Octet® R8e closely match established SPR data, ensuring reliable results.
- Kinetic Insights: Provides real-time kinetic data crucial for understanding structure-activity relationships in drug discovery.
Resource Details:
- Document type: Application Note
- Page count: 7
- Read time: 10 minutes